ArticleFrontiers in cell and developmental biology2026
NFYC upregulates KLF1 expression and activate LDHA to drive glycolysis and tumor growth in glioblastoma cells.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Metabolic reprogramming is a hallmark of glioblastoma multiforme (GBM), with lactate dehydrogenase A (LDHA) playing a key role in aerobic glycolysis. However, the upstream transcriptional mechanisms driving LDHA overexpression in GBM remain poorly understood. This study aims to investigate the transcriptional regulatory network governing LDHA-mediated glycolysis and to explore the functional roles of KLF1 and NFYC in GBM progression. Methods: Bioinformatic analysis of The Cancer Genome Atlas data was performed to assess LDHA, KLF1, and NFYC expression in glioma. glioblastoma multiforme cell lines were used for loss- and gain-of-function studies by siRNA/shRNA knockdown and overexpression, including assessments of glycolytic flux, mitochondrial metabolism, cell proliferation, and apoptosis Metabolic activity was assessed using Seahorse extracellular flux analysis. Transcriptional regulation was evaluated by dual-luciferase reporter and chromatin immunoprecipitation (ChIP) assays. Tumor growth was assessed in a subcutaneous xenograft model. Results: LDHA was significantly upregulated in GBM and associated with poor prognosis. LDHA knockdown suppressed tumor growth, glycolysis, mitochondrial respiration, and induced apoptosis. KLF1 was identified as a direct transcriptional activator of LDHA. NFYC was shown to bind the KLF1 promoter and positively regulate its expression. Functional studies demonstrated that the NFYC-KLF1-LDHA axis promotes GBM cell proliferation, inhibits apoptosis, and enhances glycolytic and mitochondrial metabolism. The oncogenic effects of NFYC were partially reversed by KLF1 knockdown, and Conclusion: This study reveals a novel hierarchical transcriptional pathway in which NFYC regulates KLF1, which in turn activates LDHA, driving aerobic glycolysis and tumor progression in GBM. Targeting the NFYC-KLF1-LDHA axis may represent a promising therapeutic strategy for glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.